Search
Raxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012. … Raxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons.
Synonyms: PA mAbCladribine
go.drugbank.com/drugs/DB00242ApprovedInvestigational[A350] Cladribine was first approved in the United States in 1993 [A263713] initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell … [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment multiple sclerosis.[A263718]
Synonyms: 2-chloro-6-amino-9-(2-deoxy-β-D-erythro-pentofuranosyl)purineHydroxyurea
go.drugbank.com/drugs/DB01005ApprovedInvestigationalHydroxyurea is a non-alkylating antineoplastic agent that was first synthesized in 1869 but was not characterized biologically until 1928. … [A262596] It was first approved by the FDA in 1998 for the treatment of sickle cell anemia in adults.
Synonyms: N-Hydroxyurea, N-CarbamoylhydroxylamineProducts: Hydroxycarbamid 1A Pharma 100 mg - Filmtabletten, Hydroxycarbamid 1A Pharma 1000 mg - FilmtablettenDiacetyl benzoyl lathyrol
go.drugbank.com/drugs/DB11260ApprovedDiacetyl benzoyl lathyrol is an active ingredient in whitening creams. It is also reported to be a skin conditioning agent.
Mixtures: The History Of Whoo Gongjinhyang Mi Luxury BbVernakalant
go.drugbank.com/drugs/DB06217ApprovedInvestigationalIntravenous formulation was approved in Europe in September 2010 as Brinavess and in Canada in April 2017. It is an investigational drug under regulatory review by FDA. … It acts as an atypical class III antiarrhythmic drug that potentiates its effect in higher heart rates.
Zolasartan
go.drugbank.com/drugs/DB20140ExperimentalZolasartan is a small molecule drug. The usage of the INN stem '-sartan' in the name indicates that Zolasartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic). … Zolasartan has a monoisotopic molecular weight of 554.05 Da.
Categories: Angiotensin II receptor antagonists, Angiotensin II Type 1 Receptor BlockersEnoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnEnoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. … It is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries.
Categories: Compounds used in a research, industrial, or household settingStreptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen
go.drugbank.com/drugs/DB10296ApprovedInvestigationalStreptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of *Streptococcus pneumoniae … The saccharides in the vaccine are prepared from purified polysaccharides that are chemically activated then conjugated to the protein carrier CRM197 to form the glycoconjugate.
Synonyms: Streptococcus pneumoniae serotype 6A capsular antigen diphtheria CRM197 protein conjugate vaccine, Streptococcus pneumoniae type 6A capsular polysaccharide diphtheria CRM197 protein conjugate antigenMixtures: PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, PREVENAR 13/0,5 ML IM ENJEKSIYON ICIN SUS. ICEREN KUL.HAZIR ENJEKTOR, 10 ADETDifelikefalin
go.drugbank.com/drugs/DB11938ApprovedInvestigational[A237615,A237620] The clinical burden of uremic pruritus in this patient population is being increasingly recognized as contributing to a significant reduction in patient quality of life, poor outcomes … [A237610] These revelations led to the study of KOR agonists as a potential treatment option in patients suffering from pruritic conditions.
Zenocutuzumab
go.drugbank.com/drugs/DB15559ApprovedInvestigationalZenocutuzumab is a low-fucose humanized full-length immunoglobulin G1 (IgG1) bispecific HER2- and HER3-directed bispecific antibody. … [L51983] In May 2026, zenocutuzumab was granted additional approval by the US FDA for use in NRG1-positive cholangiocarcinoma.